Dysbindin Facilitates Invasion and Metastasis by Promoting Phosphorylation of ERK in Epithelial Ovarian Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Apr 1

PMID 32226500

Citations 2

Authors

Xiaohui Lv

Xin Guo

Yi Ru

Fuxing Zhou

Xiaoshan Yang

Junli Ge

Jia Li

Shujuan Liu

Kuo Jiang

BiLiang Chen

Affiliations

Soon will be listed here.

Abstract

Dysbindin has been reported to be correlated with several malignancies. However, the clinical significance and biological role of dysbindin in epithelial ovarian cancer remains largely unknown. Here we demonstrated that the mRNA and protein levels of dysbindin were significantly upregulated in EOC tissues compared with normal ovarian tissues. High levels of dysbindin were significantly correlated with worse clinicopathological characteristics and poor prognosis in EOC patients. Overexpression and silencing of dysbindin promoted and inhibited, respectively, invasion and metastasis of EOC cells and . Mechanistically, dysbindin activates phosphorylation of ERK to promote the epithelial-mesenchymal transition and to mediate the invasive and metastatic ability of EOC cells. Our findings suggest that dysbindin facilitates invasion and metastasis by promoting the EMT of EOC cells and may serve as a potential therapeutic target in EOC.

Citing Articles

Dysbindin Domain-Containing 1 in Prostate Cancer: New Insights into Bioinformatic Validation of Molecular and Immunological Features.

Tram V, Ta H, Anuraga G, Thuy Dung P, Xuan D, Dey S Int J Mol Sci. 2023; 24(15).

PMID: 37569304 PMC: 10418609. DOI: 10.3390/ijms241511930.

Association of dysbindin expression with individualized postoperative prognosis and chemotherapy benefit among patients with gastric adenocarcinoma.

Qian H, Lv X, Song Q, Su R, Xie T, Wu D J Cancer. 2021; 12(22):6740-6748.

PMID: 34659563 PMC: 8518004. DOI: 10.7150/jca.60576.

References

Fang C, Guo X, Lv X, Yin R, Lv X, Wang F . Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K. J Mol Cell Biol. 2017; 9(6):504-515. PMC: 6283123. DOI: 10.1093/jmcb/mjx043. View

Hu J, Meng Y, Zhang Z, Yan Q, Jiang X, Lv Z . MARCH5 RNA promotes autophagy, migration, and invasion of ovarian cancer cells. Autophagy. 2016; 13(2):333-344. PMC: 5324849. DOI: 10.1080/15548627.2016.1256520. View

Hubbard A, Poynter J . Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012. Gynecol Oncol. 2019; 154(3):608-615. PMC: 6717673. DOI: 10.1016/j.ygyno.2019.06.025. View

Ryu Y, Lee Y, Lee K, Hwang C, Maeng J, Kim J . TRIM32 protein sensitizes cells to tumor necrosis factor (TNFα)-induced apoptosis via its RING domain-dependent E3 ligase activity against X-linked inhibitor of apoptosis (XIAP). J Biol Chem. 2011; 286(29):25729-38. PMC: 3138287. DOI: 10.1074/jbc.M111.241893. View

Mead C, Kuzyk M, Moradian A, Wilson G, Holt R, Morin G . Cytosolic protein interactions of the schizophrenia susceptibility gene dysbindin. J Neurochem. 2010; 113(6):1491-503. DOI: 10.1111/j.1471-4159.2010.06690.x. View

Torre L, Trabert B, DeSantis C, Miller K, Samimi G, Runowicz C . Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018; 68(4):284-296. PMC: 6621554. DOI: 10.3322/caac.21456. View

Bruggeman J, Koster J, Lodder P, Repping S, Hamer G . Massive expression of germ cell-specific genes is a hallmark of cancer and a potential target for novel treatment development. Oncogene. 2018; 37(42):5694-5700. PMC: 6193945. DOI: 10.1038/s41388-018-0357-2. View

Benson M, Newey S, Martin-Rendon E, Hawkes R, Blake D . Dysbindin, a novel coiled-coil-containing protein that interacts with the dystrobrevins in muscle and brain. J Biol Chem. 2001; 276(26):24232-41. DOI: 10.1074/jbc.M010418200. View

Gokhale A, Mullin A, Zlatic S, Easley 4th C, Merritt M, Raj N . The N-ethylmaleimide-sensitive factor and dysbindin interact to modulate synaptic plasticity. J Neurosci. 2015; 35(19):7643-53. PMC: 4429160. DOI: 10.1523/JNEUROSCI.4724-14.2015. View

10.

Ghiani C, DellAngelica E . Dysbindin-containing complexes and their proposed functions in brain: from zero to (too) many in a decade. ASN Neuro. 2011; 3(2). PMC: 3155195. DOI: 10.1042/AN20110010. View

11.

Radl B, Mlineritsch B . ASCO 2017-highlights of gynecological cancer. Memo. 2017; 10(4):237-239. PMC: 5725518. DOI: 10.1007/s12254-017-0371-z. View

12.

Higo M, Uzawa K, Kouzu Y, Bukawa H, Nimura Y, Seki N . Identification of candidate radioresistant genes in human squamous cell carcinoma cells through gene expression analysis using DNA microarrays. Oncol Rep. 2005; 14(5):1293-8. View

13.

Lu L, Wang J, Wu Y, Wan P, Yang G . Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling. Cancer Med. 2016; 5(12):3544-3554. PMC: 5224839. DOI: 10.1002/cam4.946. View

14.

Guo X, Lv X, Fang C, Lv X, Wang F, Wang D . Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling. Int J Cancer. 2016; 139(8):1821-9. DOI: 10.1002/ijc.30227. View

15.

Guo A, Sun J, Riley B, Thiselton D, Kendler K, Zhao Z . The dystrobrevin-binding protein 1 gene: features and networks. Mol Psychiatry. 2008; 14(1):18-29. PMC: 2859304. DOI: 10.1038/mp.2008.88. View

16.

Hayakawa Y, Sakitani K, Konishi M, Asfaha S, Niikura R, Tomita H . Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. Cancer Cell. 2016; 31(1):21-34. PMC: 5225031. DOI: 10.1016/j.ccell.2016.11.005. View

17.

Lim W, Kim H, Kim Y, Park S, Song J, Lee K . Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer cells. Bioorg Med Chem Lett. 2017; 27(23):5337-5343. DOI: 10.1016/j.bmcl.2017.09.024. View

18.

Kubota K, Kumamoto N, Matsuzaki S, Hashimoto R, Hattori T, Okuda H . Dysbindin engages in c-Jun N-terminal kinase activity and cytoskeletal organization. Biochem Biophys Res Commun. 2008; 379(2):191-5. DOI: 10.1016/j.bbrc.2008.12.017. View

19.

Tzartzeva K, Singal A . Testing for AFP in combination with ultrasound improves early liver cancer detection. Expert Rev Gastroenterol Hepatol. 2018; 12(10):947-949. DOI: 10.1080/17474124.2018.1512855. View

20.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View